The below table lists all Roche drugs that earned ... That asset could be one of the three GLP-1 agonist drugs Roche is guiding through clinical studies, that it acquired via is $2.7bn acquisition ...

Some of drugs and therapies have been evaluated in clinical trials (Table 1), mainly targeting hepatocyte death ... mediated production of hexanoic acid and activating GPR43/GLP-1 pathway, which might ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

When a GLP-1 drug is in shortage ... We summarize the approximate costs in the table below. In a 72-week trial involving more than 2,500 people with obesity or overweight and related conditions ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

With Super Bowl LIX just days away, do consumers have to be concerned about food prices when shopping for their snack ...

Pepsi's financial wellness partnership, the growing popularity of GLP-1 weight loss drugs and more top the list of core ...

After a series of public market collapses, investors and bankers have strict standards for healthcare startups hoping to IPO ...